Sanofi-aventis Group Japan (hereafter: sanofi-aventis, Headquarters: Tokyo, President: Philippe Fauchet) and Eisai Co., Ltd. (hereafter: Eisai, Headquarters: Tokyo; President & CEO: Haruo Naito) announced today that they have reached an agreement to terminate the marketing alliance on December 31, 2005 for
Rulid
Tablets 150mg (generic name: roxithromycin), a long-acting macrolide marketed by Eisai under license from sanofi-aventis. Sanofi-aventis will market the drug from January 1, 2006.
Rulid Tablets 150mg is an oral antibiotic of the macrolide class, discovered by Roussel Uclaf (now sanofi-aventis).
Rulid taken twice daily reaches therapeutic concentrations in the blood and has good tissue penetration. It has shown favorable efficacy against acne (pimples), skin infections, sinusitis, otitis media, respiratory tract infections and dental infections.
Contacts:
Media Relations Communication
sanofi-aventis Group Japan
Tel : +81-3-6301-4148 |
Corporate Communications Department
Eisai Co., Ltd.
Tel : +81-3-3817-5120 |
For Print